Prolastin Direct Program logo – support for physicians and patients

PROLASTIN DIRECT: One source for every alpha-1 need

Just 1 number connects you and your patients to comprehensive, personalized alpha-1 support: 1-800-305-7881.


Enrollment is easy

Blue form icon

Complete enrollment form

  • Download, complete, and fax the PROLASTIN DIRECT enrollment form to 1-866-588-6940
  • Prescribe PROLASTIN-C LIQUID to your patients with alpha-1
  • Choose EVERSANA as the dispensing pharmacy. EVERSANA is the exclusive dispensing pharmacy for PROLASTIN-C LIQUID
Orange umbrella icon

PROLASTIN DIRECT takes care of the rest so you and your practice can have more time managing your patients with alpha-1


The PROLASTIN DIRECT program simplifies alpha-1 management for you and your patients

A dedicated PROLASTIN-C LIQUID coordinator1

By enrolling in the PROLASTIN DIRECT program, you and your patients with alpha-1 will be assigned a dedicated PROLASTIN-C LIQUID coordinator, so that every alpha-1 treatment need can be managed through a single source.1

PROLASTIN DIRECT coordinators have a:

  • >90% success rate in obtaining patient insurance coverage for PROLASTIN-C LIQUID1
  • 98.4% treatment compliance rate for patients enrolled in the PROLASTIN DIRECT program1

See how the PROLASTIN DIRECT program simplifies the process—from enrollment to therapy to ongoing support.

PROLASTIN DIRECT insurance specialists1

PROLASTIN DIRECT insurance specialists will help provide hands-on management of the prior authorization process

  • Insurance specialists have a >90% success rate in obtaining patient coverage1

PROLASTIN DIRECT will also help identify patients in need of financial assistance who are eligible to enroll in the Assist $0 copay program—providing up to $6600 every year.

See how PROLASTIN DIRECT insurance and reimbursement specialists can help secure coverage.

Specialty pharmacy and infusion experts1

Your PROLASTIN DIRECT Alpha-1 Care Team's specialty pharmacy and infusion experts:

  • Provide 24/7 on-call support from specialty-trained registered nurses and pharmacists dedicated exclusively to alpha-1 care1
  • Provide access to a dedicated pharmacy that coordinates shipments, scheduling, and supply needs
  • Coordinate infusion therapy at a time that's convenient to your patient—at home, at a clinic, or when traveling—at no additional cost to the patient when insurance allows

Learn more about the support and infusion coordination provided by the PROLASTIN DIRECT program.

Automatic enrollment in a disease-management program1

As part of the PROLASTIN DIRECT program, patients are automatically enrolled in a disease-management program (AlphaNet®) where they receive one-on-one support from a treatment-experienced patient with alpha-1.

The AlphaNet disease-management program helps improve patient outcomes in addition to their augmentation therapy1,2:

  • Increased compliance with prescribed COPD interventions
  • 10% reduction in exacerbations
  • 21% reduction in ER visits


Enroll your patients in the PROLASTIN DIRECT program

Simply download, complete, and fax the PROLASTIN DIRECT enrollment form to 1-866-588-6940.





PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use
  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.



1. Data on file, PROLASTIN DIRECT program. 2. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31-40.